BioNxt Solutions, a cutting-edge bioscience innovator, has scored a major intellectual property win for its breakthrough sublingual multiple sclerosis therapy.

The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases.

The patent covers BioNxt’s lead candidate, BNT23001, a sublingual thin-film formulation of cladribine for multiple sclerosis (MS), and extends across all eight EAPO member states — Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, and Turkmenistan — reaching a combined population of over 200 million people. The patent is valid until June 14, 2043.

“This Eurasian patent marks a major milestone in our global commercialization strategy,” said Hugh Rogers, CEO of BioNxt.

“It comes at a pivotal time, as our large-mass animal bioequivalence study is underway. In the coming weeks, we anticipate additional national patent approvals, study results, and the launch of our human bioequivalence trial — all of which will accelerate discussions with potential global partners.”

BioNxt is advancing patent protections in other major pharmaceutical markets. The European Patent Office has issued an intention to grant, while a US Track One priority filing is in progress, alongside efforts in Canada, Australia, New Zealand, and Japan — covering some of the world’s most lucrative pharma markets.